Notably, CPZ treatment substantially increased the survival of mice bearing intracranial TMZ-resistant glioma cells, without any noticeable adverse effects such as change in animal weight or behavior, implying a potential therapeutic application for CPZ. The gene discussed is CPZ; the disease is glioma.